Golasept Tosse Grassa (Ambroxol Hydrochloride)

Golasept Tosse Grassa is indicated for the symptomatic relief of productive coughs where thick mucus impairs airway clearance.

• Management of productive cough due to acute or chronic bronchitis.
• Relief of mucus‑related symptoms in upper respiratory tract infections.
• Adjunct therapy for chronic obstructive pulmonary disease (COPD) with mucus hypersecretion.
• Supportive treatment for asthma patients experiencing thick sputum.
• Use in other respiratory conditions where mucus viscosity hampers expectoration.

The safety profile of ambroxol hydrochloride, the active component of Golasept Tosse Grassa, includes both common and less frequent adverse events.

Common

• Altered taste sensation or bitter taste in the mouth.
• Nausea or mild gastrointestinal discomfort.
• Abdominal pain or mild diarrhea.
• Headache.
• Transient skin rash or mild itching.
• Dizziness.

Serious

• Allergic reactions such as urticaria or angioedema.
• Severe skin reactions (e.g., Stevens‑Johnson syndrome).
• Hepatic enzyme elevation or liver dysfunction.
• Eosinophilia or other blood dyscrasias.
• Anaphylactic shock (rare).
• Persistent bronchospasm or worsening respiratory symptoms.

When considering Golasept Tosse Grassa, several precautionary measures should be observed.

• Do not use if you have a known hypersensitivity to ambroxol or any excipients.
• Exercise caution in patients with hepatic impairment; monitor liver function if therapy is prolonged.
• Use carefully in individuals with renal dysfunction, adjusting duration as needed.
• Pregnancy and lactation safety have not been established; consult a healthcare professional before use.
• Pediatric use is not recommended unless specifically advised by a physician.
• Avoid use during acute severe asthma exacerbations without medical supervision.
• Do not combine with other mucolytic agents containing the same active ingredient.

Potential drug interactions with Golasept Tosse Grassa should be reviewed before initiating therapy.

Avoid

• Concurrent use of multiple mucolytic or expectorant products containing ambroxol or similar agents.
• Co‑administration with drugs known to provoke bronchospasm in susceptible individuals.

Use with caution

• Anticoagulants or antiplatelet agents (possible increased bleeding risk).
• CYP2D6 substrates (ambroxol may inhibit this enzyme).
• Other respiratory medications such as bronchodilators or corticosteroids (monitor for additive effects).
• Alcohol or sedatives that may exacerbate dizziness.
• Herbal supplements that affect liver metabolism.